Association between lactate-to-albumin ratio and 28-day ICU mortality in pediatric severe pneumonia patients

乳酸/白蛋白比值与儿童重症肺炎患者28天ICU死亡率之间的关联

阅读:2

Abstract

INTRODUCTION: The lactate-to-albumin ratio (LAR) has emerged as a promising prognostic biomarker in critical care, reflecting both metabolic dysfunction and inflammatory status. However, its prognostic value in pediatric severe pneumonia remains underexplored. This study aimed to investigate the association between LAR and 28-day ICU mortality in pediatric severe pneumonia patients using data from the Paediatric Intensive Care database. METHODS: A retrospective cohort study was conducted involving 617 pediatric severe pneumonia patients admitted to the ICU between 2010 and 2018. LAR was calculated as the ratio of lactate (mmol/L) to albumin (g/dL). The primary outcome was 28-day ICU mortality. Cox proportional hazards regression models were used to assess the relationship between LAR and mortality, with restricted cubic splines (RCS) employed to explore potential nonlinear associations. Subgroup analyses were performed based on age, sex, and oxygenation status. RESULTS: A significant linear relationship was observed between LAR and 28-day ICU mortality. Each unit increase in log (LAR) was associated with a 2.51-fold higher mortality risk (HR 2.51, 95% CI: 1.73, 3.65; P < 0.001). Kaplan-Meier analysis confirmed that patients in the highest LAR tertile had significantly lower survival probabilities compared to those in the lowest tertile (log-rank P < 0.001). Subgroup analyses revealed consistent associations across age, sex, and oxygenation status, with no significant interactions (all P for interaction>0.05). CONCLUSIONS: Higher LAR levels are independently associated with increased 28-day ICU mortality in pediatric severe pneumonia patients, demonstrating a linear relationship. These findings highlight LAR as a valuable prognostic tool for early risk stratification and clinical decision-making in this population. Further multicenter studies are needed to validate these results and explore interventions targeting LAR reduction to improve outcomes. TRIAL REGISTRATION: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。